Different anthracycline derivates for reducing cardiotoxicity in cancer patients

Liposomal-encapsulated doxorubicin appears to be less cardiotoxic than conventional doxorubicin

A Cochrane review included 8 studies with a total of 1717 subjects. In all but one study the patients had a breast cancer.

Patients treated with liposomal-encapsulated doxorubicin compared with conventional doxorubicin had a lower rate of clinical heart failure (RR 0.20, 95% CI 0.05 to 0.75, 2 RCTs, 521 patients) and combined clinical and subclinical heart failure (RR = 0.38, 95% CI 0.24 to 0.59). There was no difference in the occurrence of clinical heart failure between doxorubicin and epirubicin treatment groups (RR = 0.36, 95% CI 0.12 to 1.11, 5 RCTs, 1036 patients), and in the occurrence of combined clinical and subclinical heart failure between epirubicin and liposomal-encapsulated doxorubicin treated groups (RR = 1.13, 95% CI 0.46 to 2.77).

Comment: The quality of evidence is downgraded by imprecise results (limited study size for each comparison). There are no data for children and patients with leukaemia.

Ədəbiyyat

1. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010;(5):CD005006 [Review content assessed as up-to-date: 26 November 2009]. .